Radical-mediated cyclization of a 6-chloro-9-(2-deoxy-D-erythro-pent-1- enofuranosyl)-8-(2,2-dibromovinyl)purine

Nucleosides and Nucleotides

Volumn 15, Issue 9, 1996, Pages 1447-1457

  Kittaka, Atsushi ^a   Yamada, Naoki ^a   Tanaka, Hiromichi ^a   Nakamura, Kazuo T ^a   Miyasaka, Tadashi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 9 [2 DEOXY 3,5 O (TETRAISOPROPYLDISILOXAN 1,3 DIYL) DEXTRO ERYTHRO 1 ENOFURANOSYL] 8 (2,2 DIBROMOVINYL)PURINE; PURINE NUCLEOSIDE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; VINYL DERIVATIVE;

CHEMICAL REACTION; CHEMICAL STRUCTURE; CYCLIZATION; DRUG SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 0029794540     PISSN: 07328311     EISSN: None     Source Type: Journal    
DOI: 10.1080/07328319608002446     Document Type: Review

References (32)

1. a) Rabi, J. A.; Fox, J. J. J. Org. Chem. 1972, 37, 3898-3901.
2. b) Otter, B. A.; Falco, E. A.; Fox, J. J. J. Org. Chem. 1976, 41, 3133-3137.
3. c) Otter, B. A.; Falco, E. A. Tetrahedron Lett. 1978, 4383-4386.
4. d) Ueda, T.; Usui, H.; Shuto, S.; Inoue, H. Chem. Pharm. Bull. 1984, 32, 3410-3416.
5. e) Ueda, T.; Shuto, S.; Satoh, M.; Inoue, H. Nucleosides Nucleotides, 1985, 4, 401-409.
6. f) Sano, T.; Inoue, H.; Ueda, T. Chem. Pharm. Bull. 1985, 33, 1856-1860.
7. g) Sano, T.; Inoue, H.; Ueda, T. Chem. Pharm. Bull. 1985, 33, 3595-3598.
8. h) Sano, T.; Shuto, S.; Inoue, H.; Ueda, T. Chem. Pharm. Bull. 1985, 33, 3617-3622.
9. i) Sano, T.; Ueda, T. Chem. Pharm. Bull. 1986, 34, 423-425.
10. j) Sasson, I. M.; Otter, B. A. J. Heterocyclic Chem. 1987, 24, 1439-1444.
11. k) Yoshimura, Y.; Sano, T.; Matsuda, A.; Ueda, T. Chem. Pharm. Bull. 1988, 36, 162-167.
12. l) Yoshimura, Y.; Matsuda, A.; Ueda, T. Chem. Pharm. Bull. 1989, 37, 660-664.
13. m) Yoshimura, Y.; Matsuda, A.; Ueda, T. Chem. Pharm. Bull. 1990, 38, 389-392.
14. Synthesis of 6,1′-propanouridine has been accomplished starting from D-fructose: Yoshimura, Y.; Otter, B. A.; Ueda, T.; Matsuda, A. Chem. Pharm. Bull. 1992, 40, 1761-1769.
15. For C-C bond formations at the anomeric position of nucleosides: a) Haraguchi, K.; Itoh, Y.; Tanaka, H.; Yamaguchi, K.; Miyasaka, T. Tetrahedron Lett. 1993, 34, 6913-6916. b) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Gen, E.; Miyasaka, T. J. Org. Chem. 1995, 60, 656-662. c) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Matsumoto, K.; Nakamura, K. T.; Miyasaka, T. Tetrahedron Lett. 1995, 36, 3867-3870. d) Yoshimura, Y.; Kano, F.; Miyazaki, S.; Ashida, N.; Sakata, S.; Haraguchi, K.; Itoh, Y.; Tanaka, H.; Miyasaka, T. Nucleosides Nucleotides 1996, 15, 305-324.
16. For C-C bond formations at the anomeric position of nucleosides: a) Haraguchi, K.; Itoh, Y.; Tanaka, H.; Yamaguchi, K.; Miyasaka, T. Tetrahedron Lett. 1993, 34, 6913-6916. b) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Gen, E.; Miyasaka, T. J. Org. Chem. 1995, 60, 656-662. c) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Matsumoto, K.; Nakamura, K. T.; Miyasaka, T. Tetrahedron Lett. 1995, 36, 3867-3870. d) Yoshimura, Y.; Kano, F.; Miyazaki, S.; Ashida, N.; Sakata, S.; Haraguchi, K.; Itoh, Y.; Tanaka, H.; Miyasaka, T. Nucleosides Nucleotides 1996, 15, 305-324.
17. For C-C bond formations at the anomeric position of nucleosides: a) Haraguchi, K.; Itoh, Y.; Tanaka, H.; Yamaguchi, K.; Miyasaka, T. Tetrahedron Lett. 1993, 34, 6913-6916. b) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Gen, E.; Miyasaka, T. J. Org. Chem. 1995, 60, 656-662. c) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Matsumoto, K.; Nakamura, K. T.; Miyasaka, T. Tetrahedron Lett. 1995, 36, 3867-3870. d) Yoshimura, Y.; Kano, F.; Miyazaki, S.; Ashida, N.; Sakata, S.; Haraguchi, K.; Itoh, Y.; Tanaka, H.; Miyasaka, T. Nucleosides Nucleotides 1996, 15, 305-324.
18. For C-C bond formations at the anomeric position of nucleosides: a) Haraguchi, K.; Itoh, Y.; Tanaka, H.; Yamaguchi, K.; Miyasaka, T. Tetrahedron Lett. 1993, 34, 6913-6916. b) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Gen, E.; Miyasaka, T. J. Org. Chem. 1995, 60, 656-662. c) Itoh, Y.; Haraguchi, K.; Tanaka, H.; Matsumoto, K.; Nakamura, K. T.; Miyasaka, T. Tetrahedron Lett. 1995, 36, 3867-3870. d) Yoshimura, Y.; Kano, F.; Miyazaki, S.; Ashida, N.; Sakata, S.; Haraguchi, K.; Itoh, Y.; Tanaka, H.; Miyasaka, T. Nucleosides Nucleotides 1996, 15, 305-324.
19. a) Kittaka, A.; Tanaka, H.; Odanaka, Y.; Ohnuki, K.; Yamaguchi, K.; Miyasaka, T. J. Org. Chem. 1994, 59, 3636-3641.
20. b) Kittaka, A.; Tsubaki, Y.; Tanaka, H.; Nakamura, K. T.; Miyasaka, T. Nucleosides Nucleotides 1996, 15, 97-107.
21. For the preparation of 6-chloro-9-(β-D-ribofuranosyl)purine from inosine: Zemlicka, J.; Owens, J. Nucleic Acid Chemistry; Townsend, L. B., Tipson, R. S., Eds.; John Wiley and Sons: New York, 1978; Vol. 2, pp 611-614.
22. Sakairi, N.; Hirao, I.; Zama, Y.; Ishido, Y. Nucleosides Nucleotides 1983, 2, 221-229.
23. It has been reported that hydride reduction of 1′-C-branched 2′-ketouridines gave the ribofuranosyl derivatives predominantly: see reference 2.
24. For C8 lithiation of purine nucleosides: a) Tanaka, H.; Uchida, Y.; Shinozaki, M.; Hayakawa, H.; Matsuda, A.; Miyasaka, T. Chem. Pharm. Bull. 1983, 31, 787-790. b) Hayakawa, H.; Haraguchi, K.; Tanaka, H.; Miyasaka, T. Chem. Pharm. Bull. 1987, 35, 72-79. c) Hayakawa, H.; Tanaka, H.; Sasaki, K.; Haraguchi, K.; Saitoh, T.; Takai, F.; Miyasaka, T. J. Heterocyclic Chem. 1989, 26, 189-192.
25. For C8 lithiation of purine nucleosides: a) Tanaka, H.; Uchida, Y.; Shinozaki, M.; Hayakawa, H.; Matsuda, A.; Miyasaka, T. Chem. Pharm. Bull. 1983, 31, 787-790. b) Hayakawa, H.; Haraguchi, K.; Tanaka, H.; Miyasaka, T. Chem. Pharm. Bull. 1987, 35, 72-79. c) Hayakawa, H.; Tanaka, H.; Sasaki, K.; Haraguchi, K.; Saitoh, T.; Takai, F.; Miyasaka, T. J. Heterocyclic Chem. 1989, 26, 189-192.
26. For C8 lithiation of purine nucleosides: a) Tanaka, H.; Uchida, Y.; Shinozaki, M.; Hayakawa, H.; Matsuda, A.; Miyasaka, T. Chem. Pharm. Bull. 1983, 31, 787-790. b) Hayakawa, H.; Haraguchi, K.; Tanaka, H.; Miyasaka, T. Chem. Pharm. Bull. 1987, 35, 72-79. c) Hayakawa, H.; Tanaka, H.; Sasaki, K.; Haraguchi, K.; Saitoh, T.; Takai, F.; Miyasaka, T. J. Heterocyclic Chem. 1989, 26, 189-192.
27. Corey, E. J.; Fuchs, P. L. Tetrahedron Lett. 1972, 3769-3772.
28. ++H).
29. 2 as an initiator. It is well known that radical cyclization leading to five-membered ring formations is a kinetically controlled process: a) Jasperse, C. P.; Curran, D. P.; Fevig, T. L. Chem. Rev. 1991, 91, 1237-1286. b) Beckwith, A. L. J.; Schiesser, C. H. Tetrahedron 1985, 41, 3925-3941.
30. 2 as an initiator. It is well known that radical cyclization leading to five-membered ring formations is a kinetically controlled process: a) Jasperse, C. P.; Curran, D. P.; Fevig, T. L. Chem. Rev. 1991, 91, 1237-1286. b) Beckwith, A. L. J.; Schiesser, C. H. Tetrahedron 1985, 41, 3925-3941.
31. The synthesis of an oxygen-bridged purine nucleoside fixed in the syn-conformation has been reported: Zavgodny, S. G. Tetrahedron Lett. 1981, 22, 3003-3006.
32. Kittaka, A.; Tanaka, H.; Yamada, N.; Miyasaka, T. Tetrahedron Lett. 1996, 37, 2801-2804.